BioNTech aims to develop mRNA vaccine for malaria

Pharmaceutical company BioNTech said on Monday that it wants to develop an mRNA-based vaccine to prevent malaria, one of the world’s deadliest diseases.

The Germany-based company, which developed the first widely approved COVID-19 shot with US partner Pfizer, aims to begin clinical trials for a “safe and highly effective malaria vaccine” by the end of 2022.

BioNTech has previously said it is working on a vaccine candidate for tuberculosis, with clinical trials aimed for 2022, and therapies for several forms of cancer.



Related Articles

Back to top button